Evidence map›Paper›PMID 33693174›Full record

ArticleCirculation reports2019

Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure.

Mayu Yazaki, Takeru Nabeta, Takayuki Inomata, Kenji Maemura, Takumi Ooki, Teppei Fujita, Yuichiro Iida, Yuki Ikeda, Shunsuke Ishii, Takashi Naruke and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mayu YazakiDepartment of Cardiovascular Medicine, Kitasato University School of Medicine Sagamihara Japan.
Takeru NabetaDepartment of Cardiovascular Medicine, Kitasato University School of Medicine Sagamihara Japan.
Takayuki InomataDepartment of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital Tokyo Japan.
Kenji MaemuraDepartment of Cardiovascular Medicine, Kitasato University School of Medicine Sagamihara Japan.
Takumi OokiDepartment of Cardiovascular Medicine, Kitasato University School of Medicine Sagamihara Japan.
Teppei FujitaDepartment of Cardiovascular Medicine, Kitasato University School of Medicine Sagamihara Japan.
Yuichiro IidaDepartment of Cardiovascular Medicine, Kitasato University School of Medicine Sagamihara Japan.
Yuki IkedaDepartment of Cardiovascular Medicine, Kitasato University School of Medicine Sagamihara Japan.
Shunsuke IshiiDepartment of Cardiovascular Medicine, Kitasato University School of Medicine Sagamihara Japan.
Takashi NarukeDepartment of Cardiovascular Medicine, Kitasato University School of Medicine Sagamihara Japan.
Junya AkoDepartment of Cardiovascular Medicine, Kitasato University School of Medicine Sagamihara Japan.
Kitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Heart failureHemoconcentrationKidney injuryLow cardiac outputSodium-glucose co-transporter 2 inhibitor

Identifiers

PMID33693174
PMCPMC7929704
OpenAlexW2999408254

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.